Aster DM Q2 FY27 Revenue Surges 19% YoY to ₹2,829 Cr, Op EBITDA Up 25%
Aster DM Quality Care Limited reported Q2 FY27 revenue of ₹2,829 crore, up 19% YoY. Operating EBITDA increased 25% YoY to ₹678 crore, with margins at 24.0%. Normalised PAT grew 34% to ₹281 crore. The company saw a 12% rise in patient volumes and realized INR 16.6 crore in synergies.
The significant double-digit growth in key financial metrics like revenue and EBITDA, along with positive operational indicators and synergy realization, is expected to have a substantial positive impact on the company's valuation and investor sentiment.
The company reported strong year-on-year growth in revenue, operating EBITDA, and normalised PAT, indicating positive financial performance and operational efficiency.
Aster DM Quality Care Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported a significant 19% year-on-year (YoY) growth in revenue for Q2 FY27, reaching ₹2,829 crore, compared to ₹2,382 crore in Q2 FY26. Operating EBITDA saw a robust 25% YoY increase to ₹678 crore from ₹545 crore, with the operating EBITDA margin improving by 111 basis points to 24.0% from 22.9%.
Normalised Profit After Tax (PAT) also grew by 34% YoY to ₹281 crore for Q2 FY27. The company attributed the strong performance to a 12% rise in total patient volumes and operational leverage, effective cost management, and synergy realization. Total patient volume increased to 2.18 million in Q2 FY27 from 1.95 million in Q2 FY26. The company also highlighted the realization of INR 16.6 crore in synergies in Q2 FY27, with a full synergy potential of INR 200 crore.
For the half-year ended September 30, 2026 (H1 FY27), revenue grew by 20% YoY to ₹5,429 crore, and Operating EBITDA increased by 27% YoY to ₹1,255 crore. Normalised PAT for H1 FY27 rose by 27% YoY to ₹457 crore.
The company emphasized its strategic initiatives, including investments in medical technology, expansion of clinical capabilities, and strengthening of its network. They commissioned a 32-bed CARE Cancer Institute in Raipur and expanded advanced medical technology with additions like LINAC, Digital PET-CT, robots, and cath labs. The company also noted its strong presence across India with 10,611 operational beds and plans to expand its network to over 15,000 beds by FY30 and beyond.
What to do with a filing like this
Aster DM Quality Care Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aster DM Quality Care Limited. Read the original for the full detail.